Patent Pending — Early Access Now Open

Request early access

Temporal Design Analysis is available to a limited cohort of partners ahead of broader launch. Tell us about the program you'd like reviewed — preclinical, Phase 1, Phase 2/3, or portfolio diligence — and we'll follow up to discuss fit.

All inquiries handled under appropriate confidentiality. For sponsors with a complete protocol, deeper engagements are available under mutual agreement.

What we need to score a trial

The level of detail you share determines the level of analysis we can return. You decide which tier fits the conversation you want to have.

A

Public registry preview

You share: a ClinicalTrials.gov NCT number or EU CTIS identifier — nothing else. No NDA required.

You receive: a short preview note with an indicative TDS score and the two or three temporal design questions we'd want to investigate further. Useful as a first conversation, not a final answer.

Best for: investors evaluating a target, BD teams scouting partnerships, sponsors curious how their already-registered trial would score.

B

Synopsis review under NDA

You share: a 2- to 5-page protocol synopsis covering endpoints, key timepoints, statistical analysis plan, and the rough visit schedule. Mutual NDA in place before any document is exchanged.

You receive: a TDS score with component breakdown, the most material design gaps identified, and an initial set of recommendations. Suitable for Phase 1 protocols and early-stage Phase 2 planning.

Best for: programs in protocol development, sponsors comparing two candidate designs, teams who want a fast independent read before committing to a full review.

C

Full protocol assessment under MNDA

You share: the full protocol document (and SAP, if available) under a mutual NDA — we are happy to use yours or provide ours. Protocols are scored in-house and never transmitted to third-party services.

You receive: the full Temporal Design Report (12–18 pages), the 30-minute readout call, and one round of clarifying follow-up. Standard turnaround is 5 to 10 business days.

Best for: Phase 2/3 sponsors finalizing a protocol, investors performing diligence with sponsor cooperation, CROs evaluating a sponsor's protocol on behalf of their client.

Not sure which tier fits? Use the form below — tell us what you have and what question you're trying to answer, and we'll suggest the right starting point.

Tell us about your program

Name, role, institution, and email are required. Department and interest selections help us route your inquiry to the right person.

Prefer email? Reach us directly at [email protected].